MK-2060 + clopidogrel

MK-2060 + clopidogrel is a **combination therapy** involving MK-2060, a monoclonal antibody Factor XI inhibitor, and clopidogrel, an antiplatelet small molecule, studied for prevention of thrombosis and major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD) on hemodialysis[1][2][7]. MK-2060 inhibits Factor XI in the coagulation cascade to reduce clot formation risk, while clopidogrel blocks the P2Y12 ADP receptor on platelets, reducing platelet aggregation. The combination is under investigation specifically for safety and drug interactions, given both drugs act on different parts of the clotting pathway and may increase bleeding risk[1]. MK-2060 is given intravenously or subcutaneously, and clopidogrel is administered orally. The combination is not approved and was studied in clinical trials for safety and efficacy in ESRD, especially regarding hemodialysis vascular access (arteriovenous graft thrombosis)[1][2].